{"name":"AltruBio Inc.","slug":"altrubio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ALTB-268","genericName":"ALTB-268","slug":"altb-268","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"}]}],"pipeline":[{"name":"ALTB-268","genericName":"ALTB-268","slug":"altb-268","phase":"phase_2","mechanism":"ALTB-268 is a small molecule inhibitor of the CD47/SIRPα axis.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOekoyelR2bFNHVE1HdkRMRVg4RnZDSzNpLW94STlhMDNST2JIRm9DQ1pWcVlGUUowNXJ6Y0lxekNUQ0hGUnBaV0psNTBfR0xpWFRBSFdwNUFMMWUtbGRSY1FlZE9XOTdNRGxlNXQ5eDVVWW4ybmFOT2R1Unk5azZpWVVRQUE1Qjl0bnBUWjZJaC1taEdr?oc=5","date":"2024-05-21","type":"pipeline","source":"BioPharma Dive","summary":"AltruBio lands up to $225M after shift to immune drug research - BioPharma Dive","headline":"AltruBio lands up to $225M after shift to immune drug research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPdU8ya0tlb3RoVExTTl9XckxDOWEyLThMQTJmZFJqS0FYdjRrb2lkd2gwTmk4Z0JOZ1dkVGNlVUdJUGZQbkp5bzVOR0pUYnIycmtCLTd0cE04N1g5TFROaDY4LW1Xa1FDMTFzU3F3MEdBaVI5YzZNNlhXYWdXZ3pkNU9sTEs1Q0dIX014VG9YYlJOekJsYTFsa2haQVNDdDFIS3VuN2V3?oc=5","date":"2024-05-21","type":"pipeline","source":"statnews.com","summary":"AltruBio raises $225 million to develop ulcerative colitis drug and other immune checkpoint enhancers - statnews.com","headline":"AltruBio raises $225 million to develop ulcerative colitis drug and other immune checkpoint enhancers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNZzFMUmh2MGRMQXhYejAxV3RGV2V1TFM0RXlqWkl0aFF3ZzdZcjhpeGxIVXlETENkSmNJY1I4WXAtMGdYcWdiLUx6RGZrbVVmY0oyVDBKT2JYWU4tQWVmLVllcElLSWl0UlV0Mlk1ekZsb0JXdjVnLTZ4Z2gtdnpkeEZIUWlDNXU4bjFJajhNVXhyd1NiMFU3VXdkTm5pUQ?oc=5","date":"2024-05-21","type":"pipeline","source":"The Business Journals","summary":"Former Bayer, Genentech exec's biotech raises $225 million to target ulcerative colitis - San Francisco Business Times - The Business Journals","headline":"Former Bayer, Genentech exec's biotech raises $225 million to target ulcerative colitis - San Francisco Business Times","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxOcnp2Nms1Q3I4Wm9GbVZYeFJMa3JYTWxHVTBLenZfMjlWLWEyVG0teHdpSDFoZF9jZ0xkaEhNOFRHWlhOcVM3dDV2SFlZSmRDT0E4bG42RGRKSkQyWnZsN0NPaG1rVUhWbko0cEZWMFpJeFJwc3ljbGtZU1VNeUNMQTJtblJZRFlJYjNqaks1bUFkYklsTHdyazZ0bkdxeEVMa290bFg3SGN3S3dzQ1NLUGM3anZJT21rM1pkelVDQjRxd1ZoVWI5Tm01aHpZbjY5SmNscEVoaHNxS2toU21IR3BRSlBpcXFNdXVrMlV6QlpCMjBzaG00Zl9aa2VuYng5TFZ5T05JVDBLd2ZqUkZfenZJaFI1RUtWanJKdW1Ebk5LSGFweWpGb3gwb2hwTUZFcjRPRk9TUW8?oc=5","date":"2024-05-21","type":"pipeline","source":"GlobeNewswire","summary":"AltruBio Secures up to $225M Oversubscribed Series B - GlobeNewswire","headline":"AltruBio Secures up to $225M Oversubscribed Series B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNNDBUME9XSTVIQkdiRXZqeDE5cGRDSk1meVcwempmRmE2dktpdG5tdDFOS1l5SFlnNU1DN0IzWjhJc3ZFT1ZhNVdKLUM4Q0VlS1hNcUxqWGpRazNYUmdtWEp3a2M4eHk0eUVSQ3dYQ3Z3UV9BUHh5NmtPM2doY0xENjZORkRfTXZuamFsT1ZVUHdMNUk3c3g5SFFBQUFBMnBRSDBVbF85MWVlcG9U?oc=5","date":"2023-02-12","type":"pipeline","source":"Healio","summary":"‘List doesn’t stop’ for JAK inhibitor potential in dermatology - Healio","headline":"‘List doesn’t stop’ for JAK inhibitor potential in dermatology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOdms1SHRyNG1aV25obE82UHJjV2JQRUZEeHc2WF83aHRsb25vRDBCMkNFTkJjMnlDMW41ZzlQZWlWTUNqVkVLVVVVQzg0ZkswMzQ0U2tyR0o5bzl2cllLM3NiYTdOVVF5YUh5eUZtdndLczBkdFYxNHFOOWRIb1Q2MFktVzRwek5GNmNDQng5YmdBbVBjVnBSeWhYRlNkSFBhaXkzaExsaklWeVM4YzNHT3NqVk8wUGc?oc=5","date":"2023-01-05","type":"pipeline","source":"GlobeNewswire","summary":"AltruBio to Present at Biotech Showcase™ 2023 - GlobeNewswire","headline":"AltruBio to Present at Biotech Showcase™ 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNY24yZ3JQNzJsTGJkZlZQR2cyNHJOd1RKOWwyal9qWVVBczlUVWtqamRMeFA2SlZOS2hzRVdBNW9GX051SUNZWHYwLU9zaTJpMUVsaUxwU3BQU1dXY0IxLXpLek5hRmxmcXR3c0VDQTM2UUJLSDItVHN5MVNfaUFYWUplOEo4d05XeVk2MXVjMjRrRnNGeEwxWXcxRQ?oc=5","date":"2022-03-07","type":"pipeline","source":"BioSpace","summary":"Three Influential Women in Biopharma Explain How to Break the Executive Barrier - BioSpace","headline":"Three Influential Women in Biopharma Explain How to Break the Executive Barrier","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE0xRWo5X3NhSDR0VjlqUnAxX3lyUGc0SnBhRUVKQWFnWXB5TGZ0bkYyTm5CdXdBZzlsN2dyalBDMHNKZ3FHQ2s4SjFzU3BBUXFKbHVjX2pTVmZmWVg2bnUwNGxUemhSTF90ZzhzQXRIM1pvVUh2Y2pOY1JUcw?oc=5","date":"2021-04-15","type":"pipeline","source":"Fierce Biotech","summary":"New name, new board, new focus: AltruBio relaunches with $63M series A - Fierce Biotech","headline":"New name, new board, new focus: AltruBio relaunches with $63M series A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNUDhEdmlUdnFOVU1BNndHYVBVUHVCMERlaUZFbzBhbkdVdDZIMVhuNWZIY2E1RHltN2g3NlF0STl5Z0RfczQ0NFl3dXAxcnQyaXVoZ2psSlQtcmFRV3hqbDlTRGFjaGZ4cE1sR3kwandxNXViV1V1OHRyWllVMDNhNVYxTzFQVWZlMWlmSnpSUUxlTnN5SFh4UkFtc2pHc0ZyNVg0Z0FHaWRkZ2lDdGtXdXQwZ0I4bnBqWFV2TjhfODdZLUc5NWZLc1lCTTNpNEF5bDBQYWdJVmVpYzdPMDgtRjFCT05yVkU?oc=5","date":"2021-04-15","type":"pipeline","source":"GlobeNewswire","summary":"AltruBio Raises $63 Million Series A Round To Continue Its Company Transformation - GlobeNewswire","headline":"AltruBio Raises $63 Million Series A Round To Continue Its Company Transformation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOUUFCNVBoclA0NkJ2aHk0a19lODMySGVSZVE2dWVHOUJjNm8xR0plNU1KMGJPSk1DR3U3ZmhjdFl4QlcxYm9ERnRmS1lGSVNVc3V2MldUODJVZkFIR19YWFBYOFVoSU9uZXMzWllVUnFubWNuWFlZSHNsdDdJWkdKUlhqRzcwQks2anlYbVhhdm90U1laQ2FvMkZMWQ?oc=5","date":"2021-01-13","type":"pipeline","source":"TMX Newsfile","summary":"AltruBio to Present at Biotech Showcase Digital 2021 - TMX Newsfile","headline":"AltruBio to Present at Biotech Showcase Digital 2021","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}